X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used in the development of AKR-001 (efruxifermin). It is being evaluated in the Phase II clinical trial studies for the treatment of non-cirrhotic nonalcoholic steatohepatitis.
Lead Product(s): Efruxifermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AKR-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $366.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 08, 2024
Details:
The net proceeds will be used for the development of AKR-001 (efruxifermin). It is being evaluated in the Phase II clinical trial studies for the treatment of non-cirrhotic nonalcoholic steatohepatitis.
Lead Product(s): Efruxifermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AKR-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $319.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 05, 2024
Details:
The net proceeds will be used in the development of AKR-001 (efruxifermin). It is being evaluated in the Phase II clinical trial studies for the treatment of non-cirrhotic nonalcoholic steatohepatitis.
Lead Product(s): Efruxifermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AKR-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 04, 2024
Details:
AKR-001 (efruxifermin) is a differentiated bivalent Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity of FGF21, an endogenous hormone that alleviates cellular stress and regulate metabolism throughout the body, being developed for NASH.
Lead Product(s): Efruxifermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AKR-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
AKR-001 (efruxifermin) is a differentiated bivalent Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity of FGF21, an endogenous hormone that alleviates cellular stress and regulate metabolism throughout the body, being developed for NASH.
Lead Product(s): Efruxifermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AKR-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
AKR-001 (efruxifermin) is a differentiated bivalent Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity of FGF21, an endogenous hormone that alleviates cellular stress and regulate metabolism throughout the body, being developed for NASH.
Lead Product(s): Efruxifermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AKR-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
AKR-001 (efruxifermin) is a differentiated bivalent Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity of FGF21, an endogenous hormone that alleviates cellular stress and regulate metabolism throughout the body, being developed for NASH.
Lead Product(s): Efruxifermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: EFX
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
AKR-001 (efruxifermin) is a differentiated bivalent Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity of FGF21, an endogenous hormone that alleviates cellular stress and regulate metabolism throughout the body, being developed for NASH.
Lead Product(s): Efruxifermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AKR-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
AKR-001 (efruxifermin) is a Product Candidate for NASH, Currently Being Evaluated in the Ongoing Phase 2b HARMONY and SYMMETRY trials and Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1 for NASH.
Lead Product(s): Efruxifermin
Therapeutic Area: Endocrinology Product Name: AKR-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
AKR-001 (efruxifermin) is a product candidate for NASH, currently being evaluated in the ongoing Phase 2b HARMONY and SYMMETRY trials and Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1 for NASH.
Lead Product(s): Efruxifermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AKR-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
